Advanced Filters
noise
Found 64,783 clinical trials
Y Yayun Zheng

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

This study is a single-arm, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal BCMA CAR-T cells to subjects with refractory and relapsed multiple myeloma. Eligible participants will undergo FC preconditioning after signing an informed consent form, followed by a one-time injection …

18 - 75 years of age All Phase N/A
H Hesham Rashid, Professor

Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain

Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to …

40 - 75 years of age All Phase N/A
A Arwa Ghoneim, BDS

Digital Versus Conventional Impression on Discomfort and Dental Anxiety Among Preschoolers

Background: Taking alginate impressions for preschoolers is challenging and might be disturbing for them. Therefore, intraoral scanners are suggested as a better alternative to the conventional alginate impression. Objectives: The present study aims to evaluate and compare the level of patients' discomfort, dental anxiety, gag reflex, behavior and time required …

4 - 6 years of age All Phase N/A
S Study coordinator, MsC PhD

Safety and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare

The goal of this Phase I clinical trial is to assess the pharmacokinetic availability and safety and tolerability profile of Extrato de Cannabis sativa GreenCare 79.14 mg/mL. The main question it aims to answer is: • Is the Extrato de Cannabis sativa GreenCare 79,14 mg/mL safe?

18 - 65 years of age All Phase 1
g gaelle GUETON, CRA

Can a Patient in Intensive Care be Visited by His or Her Pet?

Nearly half of all intensive care patients describe symptoms of anxiety and depression after a stay in the ICU, and one in five has genuine post-traumatic stress disorder. As a result, improving patient experience has become a priority in the ICU, and particular attention is being paid to the need …

18 years of age All Phase N/A
A Aurélien VENARA, PHD

Comparison of the Effectiveness of the Simple Puncture Compared to the Incision of an Abscess on the PiLOnidal Sinus

Pilonidal disease is a common disease characterized by the presence of abscess in the intergluteal groove. During periods of abscess, current recommendations are to make a simple incision with daily wicking of the abscess. Direct excision at this time is not recommended because there is a risk of incomplete excision. …

18 years of age All Phase N/A
J Jennifer Giordano, RN

Sacral Neuromodulation for Chronic Pelvic Pain

Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.

22 - 70 years of age Female Phase N/A
Y Yair M Daykan, MD

Local Tranexamic Acid During Vaginal Hysteractomy to Reduce Blood Loss

Assessing the efficiency of Prophylactic use of local tranexamic acid during vaginal hysterectomy to reduce blood loss during operation

20 - 90 years of age Female Phase N/A
P Prof. Dr. Christoph Röllig, MD, MSc

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy

18 years of age All Phase 2
Y Yiwen Chen, MD

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.

18 - 75 years of age All Phase 2

Simplify language using AI